Market Cap | 5.24M | P/E | 21.50 | EPS this Y | - | Ern Qtrly Grth | - |
Income | -944.49k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 8.00% |
Sales | 1.59M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 0.89 | EPS next 5Y | - | 52W High Chg | -52.00% |
Recommedations | - | Quick Ratio | 0.16 | Shares Outstanding | 24.39M | 52W Low Chg | 169.00% |
Insider Own | 43.68% | ROA | -1.74% | Shares Float | 13.74M | Beta | 1.42 |
Inst Own | - | ROE | -17.55% | Shares Shorted/Prior | -/- | Price | 0.22 |
Gross Margin | 99.77% | Profit Margin | -59.47% | Avg. Volume | 17,574 | Target Price | - |
Oper. Margin | -192.57% | Earnings Date | Dec 20 | Volume | 20,549 | Change | 7.45% |
AmeriCann, Inc. designs, develops, leases, and operates cannabis cultivation, processing, and manufacturing facilities in the United States. The company engages in the product manufacturing and greenhouse cultivation facilities for licensed cannabis business. Its flagship project is the Massachusetts Cannabis Center that is developed on a 52-acre parcel of land located in Freetown, southeastern Massachusetts. The company also provides medical cannabis and adult-use cannabis. The company was formerly known as Nevada Health Scan, Inc. and changed its name to AmeriCann, Inc. in 2014. AmeriCann, Inc. was incorporated in 2010 and is headquartered in Denver, Colorado.